216 related articles for article (PubMed ID: 26279137)
1. Rapid modification of the bone microenvironment following short-term treatment with Cabozantinib in vivo.
Haider MT; Hunter KD; Robinson SP; Graham TJ; Corey E; Dear TN; Hughes R; Brown NJ; Holen I
Bone; 2015 Dec; 81():581-592. PubMed ID: 26279137
[TBL] [Abstract][Full Text] [Related]
2. Modifying the osteoblastic niche with zoledronic acid in vivo-potential implications for breast cancer bone metastasis.
Haider MT; Holen I; Dear TN; Hunter K; Brown HK
Bone; 2014 Sep; 66(100):240-50. PubMed ID: 24971713
[TBL] [Abstract][Full Text] [Related]
3. Location matters: osteoblast and osteoclast distribution is modified by the presence and proximity to breast cancer cells in vivo.
Brown HK; Ottewell PD; Evans CA; Holen I
Clin Exp Metastasis; 2012 Dec; 29(8):927-38. PubMed ID: 22562502
[TBL] [Abstract][Full Text] [Related]
4. Preclinical evaluation of imaging biomarkers for prostate cancer bone metastasis and response to cabozantinib.
Graham TJ; Box G; Tunariu N; Crespo M; Spinks TJ; Miranda S; Attard G; de Bono J; Eccles SA; Davies FE; Robinson SP
J Natl Cancer Inst; 2014 Apr; 106(4):dju033. PubMed ID: 24634505
[TBL] [Abstract][Full Text] [Related]
5. Cabozantinib Affects Osteosarcoma Growth Through A Direct Effect On Tumor Cells and Modifications In Bone Microenvironment.
Fioramonti M; Fausti V; Pantano F; Iuliani M; Ribelli G; Lotti F; Pignochino Y; Grignani G; Santini D; Tonini G; Vincenzi B
Sci Rep; 2018 Mar; 8(1):4177. PubMed ID: 29520051
[TBL] [Abstract][Full Text] [Related]
6. Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial.
Smith DC; Smith MR; Sweeney C; Elfiky AA; Logothetis C; Corn PG; Vogelzang NJ; Small EJ; Harzstark AL; Gordon MS; Vaishampayan UN; Haas NB; Spira AI; Lara PN; Lin CC; Srinivas S; Sella A; Schöffski P; Scheffold C; Weitzman AL; Hussain M
J Clin Oncol; 2013 Feb; 31(4):412-9. PubMed ID: 23169517
[TBL] [Abstract][Full Text] [Related]
7. Cabozantinib targets bone microenvironment modulating human osteoclast and osteoblast functions.
Fioramonti M; Santini D; Iuliani M; Ribelli G; Manca P; Papapietro N; Spiezia F; Vincenzi B; Denaro V; Russo A; Tonini G; Pantano F
Oncotarget; 2017 Mar; 8(12):20113-20121. PubMed ID: 28223547
[TBL] [Abstract][Full Text] [Related]
8. Antitumor agent cabozantinib decreases RANKL expression in osteoblastic cells and inhibits osteoclastogenesis and PTHrP-stimulated bone resorption.
Stern PH; Alvares K
J Cell Biochem; 2014 Nov; 115(11):2033-8. PubMed ID: 25042887
[TBL] [Abstract][Full Text] [Related]
9. Cabozantinib Reverses Renal Cell Carcinoma-mediated Osteoblast Inhibition in Three-dimensional Coculture
Pan T; Martinez M; Hubka KM; Song JH; Lin SC; Yu G; Lee YC; Gallick GE; Tu SM; Harrington DA; Farach-Carson MC; Lin SH; Satcher RL
Mol Cancer Ther; 2020 Jun; 19(6):1266-1278. PubMed ID: 32220969
[TBL] [Abstract][Full Text] [Related]
10. Caprylic acid (C8:0) promotes bone metastasis of prostate cancer by dysregulated adipo-osteogenic balance in bone marrow.
Wang C; Wang J; Chen K; Pang H; Li X; Zhu J; Ma Y; Qiu T; Li W; Xie J; Zhang J
Cancer Sci; 2020 Oct; 111(10):3600-3612. PubMed ID: 32770813
[TBL] [Abstract][Full Text] [Related]
11. Proline/arginine-rich end leucine-rich repeat protein N-terminus is a novel osteoclast antagonist that counteracts bone loss.
Rucci N; Capulli M; Ventura L; Angelucci A; Peruzzi B; Tillgren V; Muraca M; Heinegård D; Teti A
J Bone Miner Res; 2013 Sep; 28(9):1912-24. PubMed ID: 23559035
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of prostate cancer osteoblastic progression with VEGF121/rGel, a single agent targeting osteoblasts, osteoclasts, and tumor neovasculature.
Mohamedali KA; Li ZG; Starbuck MW; Wan X; Yang J; Kim S; Zhang W; Rosenblum MG; Navone NM
Clin Cancer Res; 2011 Apr; 17(8):2328-38. PubMed ID: 21343372
[TBL] [Abstract][Full Text] [Related]
13. Cabozantinib inhibits prostate cancer growth and prevents tumor-induced bone lesions.
Dai J; Zhang H; Karatsinides A; Keller JM; Kozloff KM; Aftab DT; Schimmoller F; Keller ET
Clin Cancer Res; 2014 Feb; 20(3):617-30. PubMed ID: 24097861
[TBL] [Abstract][Full Text] [Related]
14. The MET/Vascular Endothelial Growth Factor Receptor (VEGFR)-targeted Tyrosine Kinase Inhibitor Also Attenuates FMS-dependent Osteoclast Differentiation and Bone Destruction Induced by Prostate Cancer.
Watanabe K; Hirata M; Tominari T; Matsumoto C; Fujita H; Yonekura K; Murphy G; Nagase H; Miyaura C; Inada M
J Biol Chem; 2016 Sep; 291(40):20891-20899. PubMed ID: 27539855
[TBL] [Abstract][Full Text] [Related]
15. Erythropoietin-Induced Changes in Bone and Bone Marrow in Mouse Models of Diet-Induced Obesity.
Suresh S; Alvarez JC; Dey S; Noguchi CT
Int J Mol Sci; 2020 Feb; 21(5):. PubMed ID: 32121294
[TBL] [Abstract][Full Text] [Related]
16. Cabozantinib resolves bone scans in tumor-naïve mice harboring skeletal injuries.
Doran MG; Spratt DE; Wongvipat J; Ulmert D; Carver BS; Sawyers CL; Evans MJ
Mol Imaging; 2014; 13():. PubMed ID: 25248353
[TBL] [Abstract][Full Text] [Related]
17. Endogenous parathyroid hormone-related protein compensates for the absence of parathyroid hormone in promoting bone accrual in vivo in a model of bone marrow ablation.
Zhu Q; Zhou X; Zhu M; Wang Q; Goltzman D; Karaplis A; Miao D
J Bone Miner Res; 2013 Sep; 28(9):1898-911. PubMed ID: 23716486
[TBL] [Abstract][Full Text] [Related]
18. Oestrogen receptor positive breast cancer metastasis to bone: inhibition by targeting the bone microenvironment in vivo.
Holen I; Walker M; Nutter F; Fowles A; Evans CA; Eaton CL; Ottewell PD
Clin Exp Metastasis; 2016 Mar; 33(3):211-24. PubMed ID: 26585891
[TBL] [Abstract][Full Text] [Related]
19. Plumbagin inhibits breast tumor bone metastasis and osteolysis by modulating the tumor-bone microenvironment.
Li Z; Xiao J; Wu X; Li W; Yang Z; Xie J; Xu L; Cai X; Lin Z; Guo W; Luo J; Liu M
Curr Mol Med; 2012 Sep; 12(8):967-81. PubMed ID: 22574935
[TBL] [Abstract][Full Text] [Related]
20. Attenuated Wnt/β-catenin signalling mediates methotrexate chemotherapy-induced bone loss and marrow adiposity in rats.
Georgiou KR; King TJ; Scherer MA; Zhou H; Foster BK; Xian CJ
Bone; 2012 Jun; 50(6):1223-33. PubMed ID: 22484100
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
